Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Company appoints five new independent directors to reconstituted board
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
Brings 25 years of global operations and supply chain experience to Piramal
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Subscribe To Our Newsletter & Stay Updated